摘要
目的观察不稳定心绞痛患者口服氟伐他汀后血脂和CRP、PAI-1、Fib的变化,探讨氟伐他汀应用的临床意义。方法不稳定心绞痛患者46例,常规治疗20例,常规治疗的基础上加口服氟伐他汀26例,治疗前和治疗后1周抽血查血脂、CRP、PAI-1、Fib,结果进行统计学分析。结果治疗组治疗后较治疗前血脂情况改善,同时,治疗组治疗后CRP、PAI-1、Fib较治疗前得到改善,有统计学意义。结论早期应用氟伐他汀即影响CRP、PAI-1、Fib,建议不稳定型心绞痛患者应尽量早期口服氟伐他汀治疗。
[Objective] To observe the variation of UA patient＇s lipid c-reactive protein （CRP）, fibrinogen, tissue plasminogen aetivator（t-pA） and inhibitor （PAI-1） in order to study the clinic value of fluvastin on preventing atherosclerosis. [Methods] 46 of UA patients, 20 of them with common methods, 26 of them with fluvastin. We separately assay the content of lipid fibrinogen CRP t-pA and PAI-1 before and after treatment 1 w. [Results] In group fluvastin, the variation of lipid, CRP, PAI-1, Fib has statistic sense. [Conclusions] CRP, Fib, PAI-1 can be influenced by early taking fluvastin orally, so patients with UA should be advised to use fluvastin as early as possible.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2005年第17期2644-2646,共3页
China Journal of Modern Medicine
